UroGen Pharma Management
Management criteria checks 4/4
UroGen Pharma's CEO is Liz Barrett, appointed in Jan 2019, has a tenure of 7.08 years. total yearly compensation is $4.15M, comprised of 19.9% salary and 80.1% bonuses, including company stock and options. directly owns 0.7% of the company’s shares, worth $6.57M. The average tenure of the management team and the board of directors is 5.7 years and 7.1 years respectively.
Key information
Liz Barrett
Chief executive officer
US$4.1m
Total compensation
| CEO salary percentage | 19.90% |
| CEO tenure | 7.1yrs |
| CEO ownership | 0.7% |
| Management average tenure | 5.7yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Dec 05
UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates
Nov 25UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues
Oct 06The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 10Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking
Jul 07Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop
May 17Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63
May 15
UGN-102 Approval Will Broaden Bladder Cancer Treatment Options
Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power.Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet
Feb 12UroGen: Upcoming PDUFA, Some Concerns Remain
Jan 31Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?
Nov 18UroGen Pharma: There Is Some Potential Here
Aug 28UroGen: Q3 NDA Opens Hefty Revenue Opportunity
Jun 17UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jun 14UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Apr 09UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$165m |
| Jun 30 2025 | n/a | n/a | -US$155m |
| Mar 31 2025 | n/a | n/a | -US$138m |
| Dec 31 2024 | US$4m | US$826k | -US$127m |
| Sep 30 2024 | n/a | n/a | -US$115m |
| Jun 30 2024 | n/a | n/a | -US$114m |
| Mar 31 2024 | n/a | n/a | -US$104m |
| Dec 31 2023 | US$5m | US$794k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$105m |
| Jun 30 2023 | n/a | n/a | -US$109m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$2m | US$764k | -US$110m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | -US$113m |
| Dec 31 2021 | US$4m | US$739k | -US$111m |
| Sep 30 2021 | n/a | n/a | -US$113m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$117m |
| Dec 31 2020 | US$2m | US$637k | -US$128m |
| Sep 30 2020 | n/a | n/a | -US$137m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$121m |
| Dec 31 2019 | US$26m | US$695k | -US$105m |
Compensation vs Market: Liz's total compensation ($USD4.15M) is about average for companies of similar size in the US market ($USD3.30M).
Compensation vs Earnings: Liz's compensation has been consistent with company performance over the past year.
CEO
Liz Barrett (63 yo)
Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.1yrs | US$4.15m | 0.70% $ 6.6m | |
| Chief Financial Officer | 1.3yrs | US$1.43m | 0.0049% $ 45.8k | |
| General Counsel | 5.5yrs | US$1.28m | 0.12% $ 1.1m | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Executive Vice President of Talent | 2.5yrs | no data | no data | |
| Executive Vice President of Research & Development and Technical Operations | 5.9yrs | no data | no data | |
| Chief Medical Officer | 8.2yrs | US$1.36m | 0.31% $ 2.9m | |
| Executive Vice President of Regulatory Affairs & Quality | 5.9yrs | no data | no data | |
| Executive Vice President of Medical Affairs & Clinical Development | 2.5yrs | no data | no data | |
| Chief Commercial Officer | 1.7yrs | no data | no data | |
| Senior Vice President of Business Development & Portfolio Strategy | no data | no data | no data | |
| Advisor | no data | US$699.77k | no data |
Experienced Management: URGN's management team is seasoned and experienced (5.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.1yrs | US$4.15m | 0.70% $ 6.6m | |
| Independent Director | 8.3yrs | US$193.92k | 0.0043% $ 40.2k | |
| Independent Director | 10.2yrs | US$186.42k | 0.0043% $ 40.2k | |
| Independent Chairman | 13.2yrs | US$331.91k | 0.87% $ 8.2m | |
| Independent Director | 3.3yrs | US$194.30k | 0.0043% $ 40.2k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.6yrs | US$183.92k | 0.0043% $ 40.2k | |
| Independent Director | 3.5yrs | US$196.42k | 0.0043% $ 40.2k |
Experienced Board: URGN's board of directors are considered experienced (7.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/17 21:19 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
UroGen Pharma Ltd. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Jason Kolbert | D. Boral Capital LLC. |
| Paul Choi | Goldman Sachs |